NEW YORK–(BUSINESS WIRE)–Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted priority review for dacomitinib, a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating …
Original Article: FDA Grants Priority Review to Pfizer’s Dacomitinib for Treatment of Metastatic NSCLC